Fabry Disease Clinical Trial
Official title:
Fabry Disease Registry Protocol
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: - To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease; - To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care; - To characterize and describe the Fabry population as a whole; - To evaluate the long-term safety and effectiveness of Fabrazyme® Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.
Status | Recruiting |
Enrollment | 9000 |
Est. completion date | January 31, 2034 |
Est. primary completion date | January 31, 2034 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria - Fabry Registry: All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte aGAL (alpha-galactosidase) enzyme activity and/or mutation(s) in the gene coding for aGAL. - Fabry Pregnancy Sub-registry: - Eligible women must: - be enrolled in the Fabry Registry. - be pregnant, or have been pregnant with appropriate medical documentation available. - provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed. Exclusion Criteria Fabry Registry: There are no exclusion criteria. Fabry Pregnancy Sub-registry: There are no exclusion criteria. |
Country | Name | City | State |
---|---|---|---|
Argentina | Investigational Site Number : 153130 | Buenos Aires | |
Argentina | Investigational Site Number : 153172 | Caba | Buenos Aires |
Argentina | Investigational Site Number : 153194 | Catamarca | |
Argentina | Investigational Site Number : 153032 | Ciudad Autónoma de Buenos Aires | Buenos Aires |
Argentina | Investigational Site Number : 032005 | La Rioja | |
Argentina | Investigational Site Number : 032004 | Santa Fe | |
Australia | Investigational Site Number : 151002 | Adelaide | South Australia |
Australia | Investigational Site Number : 153063 | Herston | Queensland |
Australia | Investigational Site Number : 153040 | Parkville | Victoria |
Australia | Investigational Site Number : 153090 | Perth | Western Australia |
Australia | Investigational Site Number : 036013 | Westmead | New South Wales |
Australia | Investigational Site Number : 151069 | Westmead | New South Wales |
Belgium | Investigational Site Number : 150722 | Antwerpen | |
Belgium | Investigational Site Number : 153133 | Antwerpen | |
Belgium | Investigational Site Number : 153001 | Brussels | |
Belgium | Investigational Site Number : 150517 | Bruxelles | |
Belgium | Investigational Site Number : 0560008 | Jette | |
Belgium | Investigational Site Number : 151668 | Leuven | |
Belgium | Investigational Site Number : 154275 | Liège | |
Belgium | Investigational Site Number : 153100 | Seraing | |
Brazil | Medicordis Site Number : 076009 | Brasília | Distrito Federal |
Brazil | PUC Campinas - Sociedade Campineira de Educaçao e Instruçao Site Number : 076013 | Campinas | São Paulo |
Brazil | Hospital Geral e Maternidade de Cuiabá Site Number : 076006 | Cuiabá | Mato Grosso |
Brazil | Instituto do Rim do Paraná Site Number : 076004 | Curitiba | Paraná |
Brazil | Clínica Senhor do Bonfim LTDA Site Number : 076008 | Feira de Santana | Bahia |
Brazil | Hospital Universitário Professor Polydoro Ernani de São Thiago - UFSC Site Number : 076012 | Florianopolis | Santa Catarina |
Brazil | Serviço de Terapia Renal de Ourinhos Site Number : 076011 | Ourinhos | São Paulo |
Brazil | Instituto de Medicina Integral Professor Fernando Figueira - IMIP Site Number : 076005 | Recife | Pernambuco |
Brazil | Instituto de Genética e Erros Inatos do Metabolismo - IGEIM Site Number : 076001 | São Paulo | |
Brazil | Saúde Center Clínica - Clínica Médica Nossa Senhora de Fátima Site Number : 076002 | Tapejara | Rio Grande Do Sul |
Brazil | CTDR - Centro de Tratamento de Doenças Renais EIRELI Site Number : 076007 | Uberlândia | Minas Gerais |
Bulgaria | Investigational Site Number : 100001 | Sofia | |
Bulgaria | Investigational Site Number : 153169 | Sofia | |
Canada | Investigational Site Number : 124014 | Calgary | Alberta |
Canada | Investigational Site Number : 124002 | Edmonton | Alberta |
Canada | Investigational Site Number : 124008 | Halifax | Nova Scotia |
Canada | Investigational Site Number : 124021 | London | Ontario |
Canada | Investigational Site Number : 124022 | Moncton | New Brunswick |
Canada | Investigational Site Number : 124013 | Montreal | Quebec |
Canada | Investigational Site Number : 124001 | Sherbrooke | Quebec |
Canada | Investigational Site Number : 124023 | St. John's | Newfoundland and Labrador |
Canada | Investigational Site Number : 124006 | Toronto | Ontario |
Canada | Investigational Site Number : 124009 | Toronto | Ontario |
Canada | Investigational Site Number : 124010 | Vancouver | British Columbia |
Canada | Investigational Site Number : 124011 | Vancouver | British Columbia |
Canada | Investigational Site Number : 124019 | Winnipeg | Manitoba |
Chile | Investigational Site Number : 152004 | Antofagasta | |
Chile | Investigational Site Number : 152001 | Coquimbo | |
Chile | Investigational Site Number : 152003 | Iquique | |
Chile | Investigational Site Number : 152005 | Vallenar | |
China | Investigational Site Number : 1560003 | Hangzhou | |
China | Investigational Site Number : 1560002 | Jinan | |
China | Investigational Site Number : 1560004 | Nanjing | |
Colombia | Investigational Site Number : 170001 | Bogotá | |
Croatia | Investigational Site Number : 1910001 | Rijena | |
Croatia | Investigational Site Number : 1910002 | Zagreb | |
Czechia | Investigational Site Number : 153126 | Praha 2 | |
Denmark | Investigational Site Number : 153041 | Copenhagen | |
Denmark | Investigational Site Number : 151229 | København Ø | |
Estonia | Investigational Site Number : 153106 | Tartu | |
Finland | Investigational Site Number : 153024 | Turku | |
France | Investigational Site Number : 250005 | Bordeaux | |
France | Investigational Site Number : 250002 | BRON Cedex | |
France | Investigational Site Number : 250001 | Garches | |
France | Investigational Site Number : 250007 | Lille | |
France | Investigational Site Number : 250003 | LIMOGES Cedex | |
France | Investigational Site Number : 250006 | Marseille | |
France | Investigational Site Number : 250004 | Saint Priest en Jarez | |
France | Investigational Site Number : 250009 | Strasbourg | |
Germany | Investigational Site Number : 153013 | Berlin | |
Germany | Investigational Site Number : 154150 | Gießen | |
Germany | Investigational Site Number : 153147 | Münster | |
Germany | Investigational Site Number : 153011 | Würzburg | |
Hong Kong | Investigational Site Number : 344001 | Kowloon | |
Hungary | Investigational Site Number : 3480002 | Budapest | |
Hungary | Investigational Site Number : 3480003 | Létavértes | |
Hungary | Investigational Site Number : 3480005 | Pécs | |
Hungary | Investigational Site Number : 3480004 | Sopron | |
India | Investigational Site Number : 356003 | Ahmedabad | |
India | Investigational Site Number : 356001 | Kolkata | |
India | Investigational Site Number : 3560004 | Secunderabad | |
India | Investigational Site Number : 356002 | Vellore | |
Indonesia | Investigational Site Number : 360001 | Jakarta | |
Italy | Investigational Site Number : 380002 | Bassano Del Grappa (VI) | |
Italy | Investigational Site Number : 380004 | Firenze | |
Italy | Investigational Site Number : 380013 | Firenze | |
Italy | Investigational Site Number : 380005 | Genova | |
Italy | Investigational Site Number : 380006 | Milano | |
Italy | Investigational Site Number : 380009 | Milano | |
Italy | Investigational Site Number : 380003 | Modena | |
Italy | Investigational Site Number : 380010 | Monza (MB) | |
Italy | Investigational Site Number : 380008 | Napoli | |
Italy | Investigational Site Number : 380007 | Rimini | |
Italy | Investigational Site Number : 380012 | Roma | |
Italy | Investigational Site Number : 380011 | Torino | |
Italy | Investigational Site Number : 380001 | Udine | |
Italy | Investigational Site Number : 380014 | Vittoria (RG) | |
Japan | Investigational Site Number : 153205 | Abeno-ku | Osaka |
Japan | Investigational Site Number : 153217 | Chiba | |
Japan | Investigational Site Number : 392007 | Kobe-shi, Hyogo | |
Japan | Investigational Site Number : 153201 | Nangoku-shi | Kochi |
Japan | Investigational Site Number : 392006 | Niigata-shi | Niigata |
Japan | Investigational Site Number : 153204 | Setagaya | Tokyo |
Korea, Republic of | Investigational Site Number : 154246 | Busan | |
Korea, Republic of | Investigational Site Number : 153191 | Daejeon | |
Korea, Republic of | Investigational Site Number : 153225 | Jeonnam | |
Korea, Republic of | Investigational Site Number : 151149 | Seoul | |
Korea, Republic of | Investigational Site Number : 153180 | Seoul | |
Korea, Republic of | Investigational Site Number : 153188 | Seoul | |
Korea, Republic of | Investigational Site Number : 153192 | Seoul | |
Korea, Republic of | Investigational Site Number : 153196 | Seoul | |
Korea, Republic of | Investigational Site Number : 153212 | Seoul | |
Korea, Republic of | Investigational Site Number : 153222 | Seoul | |
Korea, Republic of | Investigational Site Number : 154273 | Suwon-si | |
Korea, Republic of | Investigational Site Number : 154148 | Yangsan | Gyeongsangnam-do |
Korea, Republic of | Investigational Site Number : 153178 | Yangsan-si | Gyeongsangnam-do |
Kuwait | Investigational Site Number : 154225 | Kuwait | |
Lithuania | Investigational Site Number : 154244 | Vilnius | |
Lithuania | Investigational Site Number : 154652 | Vilnius | |
Malaysia | Investigational Site Number : 458001 | Jalan Pahang | |
Malaysia | Investigational Site Number : 458002 | Kuala Lumpur | |
Norway | Investigational Site Number : 153141 | Bergen | |
Peru | Investigational Site Number : 604002 | Callao | |
Philippines | Investigational Site Number : 608001 | Manila | |
Poland | Investigational Site Number : 150575 | Warszawa | |
Portugal | Investigational Site Number : 620005 | Lisboa | |
Portugal | Investigational Site Number : 620001 | Porto | |
Romania | Investigational Site Number : 154099 | Bucuresti | |
Romania | Investigational Site Number : 154164 | Bucuresti | |
Romania | Investigational Site Number : 153081 | Cluj-Napoca | |
Russian Federation | Investigational Site Number : 643001 | Moscow | |
Russian Federation | Investigational Site Number : 643003 | Nizhny Novgorod | |
Russian Federation | Investigational Site Number : 643002 | Saint-Peterburg | |
Saudi Arabia | Investigational Site Number : 682002 | Al Mubarraz | |
Serbia | Investigational Site Number : 6880001 | Novi Sad | |
Singapore | Investigational Site Number : 702001 | Singapore | |
Slovakia | Investigational Site Number : 703001 | Bratislava | |
Slovenia | Investigational Site Number : 705001 | Slovenj Gradec | |
Spain | Investigational Site Number : 154135 | Barakaldo | |
Spain | Investigational Site Number : 153067 | Barcelona | |
Spain | Investigational Site Number : 153077 | Barcelona | |
Spain | Investigational Site Number : 153237 | Barcelona | |
Spain | Investigational Site Number : 154123 | Barcelona | |
Spain | Investigational Site Number : 154147 | Barcelona | |
Spain | Investigational Site Number : 154204 | Barcelona | |
Spain | Investigational Site Number : 154146 | La Coruña | |
Spain | Investigational Site Number : 154159 | La Coruña | |
Spain | Investigational Site Number : 154136 | Tarragona | |
Spain | Investigational Site Number : 153213 | Vigo | |
Sweden | Investigational Site Number : 153050 | Göteborg | |
Sweden | Investigational Site Number : 151484 | Stockholm | |
Taiwan | Investigational Site Number : 154093 | Chiayi | |
Taiwan | Investigational Site Number : 152152 | Hualien | |
Taiwan | Investigational Site Number : 152244 | Kaohsiung | |
Taiwan | Investigational Site Number : 153088 | Kaohsiung City | |
Taiwan | Investigational Site Number : 152246 | Kaohsiung Hsien, | |
Taiwan | Investigational Site Number : 151534 | New Taipei City | |
Taiwan | Investigational Site Number : 151500 | Putz City, Chia-yi | |
Taiwan | Investigational Site Number : 151181 | Taichung | |
Taiwan | Investigational Site Number : 151179 | Taichung City | |
Taiwan | Investigational Site Number : 152153 | Tainan | |
Taiwan | Investigational Site Number : 153248 | Tainan | |
Taiwan | Investigational Site Number : 151182 | Taipei | |
Taiwan | Investigational Site Number : 152226 | Taipei | |
Taiwan | Investigational Site Number : 152321 | Taipei | |
Taiwan | Investigational Site Number : 153158 | Tao Yuan County | |
Thailand | Investigational Site Number : 764001 | Bangkok | |
Thailand | Investigational Site Number : 764003 | Bangkok | |
Thailand | Investigational Site Number : 764004 | Bangkok | |
Thailand | Investigational Site Number : 764005 | Khon Kaen | |
United Kingdom | Investigational Site Number : 154196 | Belfast | |
United Kingdom | Investigational Site Number : 152287 | Birmingham | |
United Kingdom | Investigational Site Number : 151340 | Cambridge | Cambridgeshire |
United Kingdom | Investigational Site Number : 150303 | London | |
United Kingdom | Investigational Site Number : 151123 | London | |
United Kingdom | Investigational Site Number : 151646 | London | |
United Kingdom | Investigational Site Number : 150455 | Manchester | |
United Kingdom | Investigational Site Number : 152361 | Salford | |
United States | University of Michigan Pediatrics Site Number : 840107 | Ann Arbor | Michigan |
United States | John Hopkins Site Number : 840044 | Baltimore | Maryland |
United States | Ochsner Medical Center Site Number : 840120 | Baton Rouge | Louisiana |
United States | Billings Clinic Site Number : 840118 | Billings | Montana |
United States | University of Alabama Birmingham- Nephrology Site Number : 840018 | Birmingham | Alabama |
United States | University of Alabama Birmingham- Nephrology Site Number : 840073 | Birmingham | Alabama |
United States | Boston Children's Hospital Site Number : 840092 | Boston | Massachusetts |
United States | Brigham and Women's Hospital-Neurology Site Number : 840103 | Boston | Massachusetts |
United States | Massachusetts General Hospital-Genetics Site Number : 840062 | Boston | Massachusetts |
United States | Carolinas Medical Center Site Number : 840065 | Charlotte | North Carolina |
United States | University of Virginia School of Medicine-Pediatrics Site Number : 840078 | Charlottesville | Virginia |
United States | Ann and Robert Lurie Children's Hospital Site Number : 840013 | Chicago | Illinois |
United States | Rush University Medical Center Genetics Site Number : 840079 | Chicago | Illinois |
United States | Cincinnati Children's Hospital-Genetics Site Number : 840033 | Cincinnati | Ohio |
United States | Cleveland Clinic Foundation Pediatrics Site Number : 840048 | Cleveland | Ohio |
United States | UHCMC Site Number : 840119 | Cleveland | Ohio |
United States | Nationwide Children's Hospital Site Number : 840091 | Columbus | Ohio |
United States | Ohio State University Department of Genetics Site Number : 840097 | Columbus | Ohio |
United States | University of Missouri Health System Department of Genetics Site Number : 840031 | Columibia | Missouri |
United States | University Hematology Oncology Site Number : 840075 | Coral Springs | Florida |
United States | Baylor Research Center Site Number : 840058 | Dallas | Texas |
United States | Geisinger Site Number : 840111 | Danville | Pennsylvania |
United States | Emory University School of Medicine- Human Genetics Site Number : 840060 | Decatur | Georgia |
United States | University of Colorado at Denver Genetics Site Number : 840068 | Denver | Colorado |
United States | Children's Hospital of Michigan Site Number : 840066 | Detroit | Michigan |
United States | LSD Data Registry Site LLC Site Number : 840094 | Dublin | Ohio |
United States | Duke University Medical Center Genetics Dept Site Number : 840045 | Durham | North Carolina |
United States | O&O Alpan, LLC Site Number : 840025 | Fairfax | Virginia |
United States | Cook Children's Health Care System Site Number : 840024 | Fort Worth | Texas |
United States | University of Florida Dept of Genetics Site Number : 840083 | Gainesville | Florida |
United States | Infusion Associates Site Number : 840050 | Grand Rapids | Michigan |
United States | Spectrum for Health Site Number : 840019 | Grand Rapids | Michigan |
United States | Greenwood Genetcs Site Number : 840055 | Greenville | South Carolina |
United States | Joseph M. Sanzari Children's Hospital Site Number : 840101 | Hackensack | New Jersey |
United States | Shodair Children's Hospital Site Number : 840090 | Helena | Montana |
United States | Penn State University Medical Center-Neurology Site Number : 840104 | Hershey | Pennsylvania |
United States | Indianapolis University School of Medicine Site Number : 840027 | Indianapolis | Indiana |
United States | University of Iowa Site Number : 840032 | Iowa City | Iowa |
United States | University of California at Irvine Site Number : 840036 | Irvine | California |
United States | The Atwal Clinic Site Number : 840112 | Jacksonville | Florida |
United States | University of Florida Pediatrics Genetics Site Number : 840121 | Jacksonville | Florida |
United States | University Of Kansas Medical Center Site Number : 840071 | Kansas City | Kansas |
United States | Children's Specialty Center of Nevada Site Number : 840008 | Las Vegas | Nevada |
United States | Arkansas Childrens Hospital Site Number : 840109 | Little Rock | Arkansas |
United States | University of Arkansas for Medical Sciences Site Number : 840113 | Little Rock | Arkansas |
United States | Southern California Permanente Medical Group Site Number : 840108 | Los Angeles | California |
United States | UCLA School Of Medicine Site Number : 840088 | Los Angeles | California |
United States | USC Health Sciences Center Dept of Genetics Site Number : 840082 | Los Angeles | California |
United States | University of Louisville- Genetics Site Number : 840030 | Louisville | Kentucky |
United States | Northwell Health Site Number : 840102 | Manhasset | New York |
United States | University Of Miami SOM Site Number : 840006 | Miami | Florida |
United States | Children's Hospital of Wisconsin-Pediatrics Site Number : 840054 | Milwaukee | Wisconsin |
United States | Children's Health Care Site Number : 840114 | Minneapolis | Minnesota |
United States | Children's Hospital and Clinics of Minnesota Site Number : 840046 | Minneapolis | Minnesota |
United States | University of Minnesota Medical Center Pediatrics Site Number : 840076 | Minneapolis | Minnesota |
United States | Atlantic Health System Site Number : 840099 | Morristown | New Jersey |
United States | Vanderbilt University Hospital-Pediatrics Site Number : 840049 | Nashville | Tennessee |
United States | St. Peter's University Hospital Site Number : 840016 | New Brunswick | New Jersey |
United States | Yale Site Number : 840047 | New Haven | Connecticut |
United States | Tulane University Medical Center Site Number : 840001 | New Orleans | Louisiana |
United States | Icahn School of Medicine Site Number : 840080 | New York | New York |
United States | Metropolitan Hospital Center Site Number : 840110 | New York | New York |
United States | New York University School Of Medicine Site Number : 840040 | New York | New York |
United States | Children's Hospital of the Kings Daughters Site Number : 840072 | Norfolk | Virginia |
United States | Children's Hospital Oakland Site Number : 840029 | Oakland | California |
United States | University of Nebraska Medical Center- Pediatrics Site Number : 840084 | Omaha | Nebraska |
United States | Children's Hospital of Orange County Site Number : 840074 | Orange | California |
United States | Stanford Unviersity MC Dept of Genetics Site Number : 840022 | Palo Alto | California |
United States | St. Joseph's Children's Hospital Site Number : 840057 | Paterson | New Jersey |
United States | Children's Hospital of Philadelphia HUP Medical Genetics Site Number : 840089 | Philadelphia | Pennsylvania |
United States | Children's Hospital of Philadelphia Site Number : 840034 | Philadelphia | Pennsylvania |
United States | Phoenix Children's Hospital Site Number : 840003 | Phoenix | Arizona |
United States | University of Pittsburgh Site Number : 840023 | Pittsburgh | Pennsylvania |
United States | Maine Medical Center Pediatrics Site Number : 840064 | Portland | Maine |
United States | Oregon Health & Science University Site Number : 840116 | Portland | Oregon |
United States | Rhode Island Hospital Genetics Site Number : 840053 | Providence | Rhode Island |
United States | University of Rochester Medical Center SOM Site Number : 840105 | Rochester | New York |
United States | Kaiser Permanente Hospital Site Number : 840042 | Sacramento | California |
United States | UC Davis MIND Institute Site Number : 840010 | Sacramento | California |
United States | Washington University of St. Louis Site Number : 840100 | Saint Louis | Missouri |
United States | University of Utah Department of Medical Genetics Site Number : 840043 | Salt Lake City | Utah |
United States | Loma Linda University Children's Hospital Site Number : 840117 | San Bernardino | California |
United States | University of California at San Diego Site Number : 840007 | San Diego | California |
United States | University of California at San Francisco Site Number : 840051 | San Francisco | California |
United States | Seattle Children's Hospital Site Number : 840028 | Seattle | Washington |
United States | University Of Washington Medical Center Site Number : 840059 | Seattle | Washington |
United States | Baystate Health Site Number : 840002 | Springfield | Massachusetts |
United States | State University of New York Site Number : 840052 | Syracuse | New York |
United States | Multicare Health System ¿ Mary Bridge Childrens Hospital Site Number : 840115 | Tacoma | Washington |
United States | University of Florida-Genetics Site Number : 840096 | Tampa | Florida |
United States | University of Arizona Site Number : 840015 | Tucson | Arizona |
United States | New York Medical College Site Number : 840039 | Valhalla | New York |
United States | Children's National Medical Center Site Number : 840067 | Washington | District of Columbia |
Vietnam | Investigational Site Number : 154212 | Hanoi |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States, Vietnam, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Hong Kong, Hungary, India, Indonesia, Italy, Japan, Korea, Republic of, Kuwait, Lithuania, Malaysia, Norway, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Taiwan, Thailand, United Kingdom,
Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Marodi L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol Genet Genomic Med. 2018 Apr 12;6(4):492-503. doi: 10.1002/mgg3.389. Online ahead of print. — View Citation
Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, Warnock DG, Wilcox WR. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13. — View Citation
Wilcox WR, Feldt-Rasmussen U, Martins AM, Ortiz A, Lemay RM, Jovanovic A, Germain DP, Varas C, Nicholls K, Weidemann F, Hopkin RJ. Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. JIMD Rep. 2018;38:45-51. doi: 10.1007/8904_2017_28. Epub 2017 May 17. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fabry Registry: To evaluate the long-term safety and effectiveness of Fabrazyme® | The primary purpose of this Registry is to describe the development and progression of Fabry disease in a representative global population. As Fabry is not a well-described disease this longitudinal program has a wide variety of "primary" outcomes including antibody testing as well as complication outcomes (eg, QoL, cognitive testing) which are measured over time. Additionally, as it is subject to what is collected by clinical sites at the time of visit it is unknown the amount of data that will be available for analyses. | 33 years | |
Primary | Fabry Pregnancy Sub-registry: pregnancy outcomes, including complications and infant growth | The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Fabry disease during pregnancy, regardless of whether they receive disease-specific therapy, such as ERT with agalsidase beta.
This Sub-registry augments the routine monitoring and data collection recommended by the Fabry Registry. The Sub-registry aims to collect patient assessments from the ante- and perinatal periods and postpartum follow-up. Neonatal assessments and periodic pediatric assessments will also be collected. |
33 years | |
Secondary | Fabry Register: Monitor factors associated with the efficacy of Fabry disease treatments | A secondary endpoint is to monitor those factors associated with the efficacy of Fabry disease treatments. | 33 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04893889 -
Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.
|
N/A | |
Completed |
NCT04455230 -
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
|
Phase 1/Phase 2 | |
Completed |
NCT01218659 -
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
|
Phase 3 | |
Completed |
NCT00304512 -
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
|
Phase 2 | |
Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
Completed |
NCT03500094 -
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
|
Phase 3 | |
Withdrawn |
NCT04143958 -
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
|
Phase 4 | |
Recruiting |
NCT02994303 -
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy
|
N/A | |
Completed |
NCT01947634 -
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
|
N/A | |
Recruiting |
NCT01695161 -
Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.
|
N/A | |
Completed |
NCT01853852 -
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
|
Phase 1 | |
Completed |
NCT00701415 -
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
|
Phase 3 | |
Completed |
NCT00068107 -
Dosing Study of Replagal in Patients With Fabry Disease
|
Phase 2 | |
Completed |
NCT01997489 -
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
|
Phase 4 | |
Recruiting |
NCT06007768 -
Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
|
||
Recruiting |
NCT05698901 -
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
|
||
Active, not recruiting |
NCT03305250 -
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease
|
N/A | |
Terminated |
NCT00526071 -
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
|
Phase 2 | |
Active, not recruiting |
NCT03566017 -
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
|
Phase 3 | |
Recruiting |
NCT06065605 -
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
|